{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:26Z","timestamp":1792784966097,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Union\u2019s Horizon 2020 Research and Innovation Programme","award":["826121"],"award-info":[{"award-number":["826121"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA223140"],"award-info":[{"award-number":["R21CA223140"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007137","name":"Texas Children's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007137","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020187","name":"Macy Easom Cancer Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020187","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cancer Prevention Research Institution of Texas","award":["RP180674"],"award-info":[{"award-number":["RP180674"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hepatoblastoma (HB) is the most common pediatric liver malignancy. High-risk patients have poor survival, and current chemotherapies are associated with significant toxicities. Targeted therapies are needed to improve outcomes and patient quality of life. Most HB cases are\n                    <jats:italic>TP53<\/jats:italic>\n                    wild-type; therefore, we hypothesized that targeting the p53 regulator Murine double minute 4 (MDM4) to reactivate p53 signaling may show efficacy.\n                    <jats:italic>MDM4<\/jats:italic>\n                    expression was elevated in HB patient samples, and increased expression was strongly correlated with decreased expression of p53 target genes. Treatment with NSC207895 (XI-006), which inhibits MDM4 expression, or ATSP-7041, a stapled peptide dual inhibitor of MDM2 and MDM4, showed significant cytotoxic and antiproliferative effects in HB cells. Similar phenotypes were seen with short hairpin RNA (shRNA)-mediated inhibition of\n                    <jats:italic>MDM4<\/jats:italic>\n                    . Both NSC207895 and ATSP-7041 caused significant upregulation of p53 targets in HB cells. Knocking-down\n                    <jats:italic>TP53<\/jats:italic>\n                    with shRNA or overexpressing\n                    <jats:italic>MDM4<\/jats:italic>\n                    led to resistance to NSC207895-mediated cytotoxicity, suggesting that this phenotype is dependent on the MDM4-p53 axis. MDM4 inhibition also showed efficacy in a murine model of HB with significantly decreased tumor weight and increased apoptosis observed in the treatment group. This study demonstrates that inhibition of MDM4 is efficacious in HB by upregulating p53 tumor suppressor signaling.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-82542-4","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T06:10:36Z","timestamp":1612332636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Sarah E.","family":"Woodfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roma H.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayushi P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryana M.","family":"Ibarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel R.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen F.","family":"Sarabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Badachhape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"Starosolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan B.","family":"Ghaghada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Sumazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Allen","family":"Annis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"L\u00f3pez-Terrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev A.","family":"Vasudevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"82542_CR1","doi-asserted-by":"crossref","unstructured":"Farazi, P. A. & DePinho, R. A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674 687 (2006).","DOI":"10.1038\/nrc1934"},{"key":"82542_CR2","doi-asserted-by":"crossref","unstructured":"Czauderna, P. et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr. Opin. Pediatr. 26, 19 28 (2014).","DOI":"10.1097\/MOP.0000000000000046"},{"key":"82542_CR3","unstructured":"Hiyama, E. Pediatric hepatoblastoma: diagnosis and treatment. Transl. Pediatr. 3, 293 299 (2014)."},{"key":"82542_CR4","doi-asserted-by":"crossref","unstructured":"Spector, L. G. & Birch, J. The epidemiology of hepatoblastoma. Pediatr. Blood Cancer 59, 776 779 (2012).","DOI":"10.1002\/pbc.24215"},{"key":"82542_CR5","doi-asserted-by":"crossref","unstructured":"Hubbard, A. K., Spector, L. G., Fortuna, G., Marcotte, E. L. & Poynter, J. N. Trends in international incidence of pediatric cancers in children under 5 years of age: 1988\u20132012. JNCI Cancer Spectr. 3, pkz007 (2019).","DOI":"10.1093\/jncics\/pkz007"},{"key":"82542_CR6","doi-asserted-by":"crossref","unstructured":"Lupo, P. J. et al. Association between birth defects and cancer risk among children and adolescents in a population-based assessment of 10 million live births. JAMA Oncol. 5, (2019).","DOI":"10.1001\/jamaoncol.2019.1215"},{"key":"82542_CR7","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/pbc.22088","volume":"53","author":"RL Meyers","year":"2009","unstructured":"Meyers, R. L. et al. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children\u2019s Oncology Group. Pediatr. Blood Cancer 53, 1016\u20131022 (2009).","journal-title":"Pediatr. Blood Cancer"},{"key":"82542_CR8","doi-asserted-by":"crossref","unstructured":"Meyers, R. L., Tiao, G., Goyet, J. de V. de, Superina, R. & Aronson, D. C. Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Curr. Opin. Pediatr. 26, 29 36 (2014).","DOI":"10.1097\/MOP.0000000000000042"},{"key":"82542_CR9","doi-asserted-by":"crossref","unstructured":"Watanabe, K. Current chemotherapeutic approaches for hepatoblastoma. Int. J. Clin. Oncol. 18, 955 961 (2013).","DOI":"10.1007\/s10147-013-0616-8"},{"key":"82542_CR10","doi-asserted-by":"crossref","unstructured":"Sivaprakasam, P., Gupta, A. A., Greenberg, M. L., Capra, M. & Nathan, P. C. Survival and long-term outcomes in children with hepatoblastoma treated with continuous infusion of cisplatin and doxorubicin. J. Pediatr. Hematol. Oncol. 33, e226 30 (2011).","DOI":"10.1097\/MPH.0b013e31821f0eaf"},{"key":"82542_CR11","doi-asserted-by":"crossref","unstructured":"Zsiros, J. et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol. 14, 834 842 (2013).","DOI":"10.1016\/S1470-2045(13)70272-9"},{"key":"82542_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/1078-0432.CCR-12-0053","volume":"19","author":"Q Li","year":"2013","unstructured":"Li, Q. & Lozano, G. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin. Cancer Res. 19, 34\u201341 (2013).","journal-title":"Clin. Cancer Res."},{"key":"82542_CR13","doi-asserted-by":"crossref","unstructured":"Duffy, M. J. et al. p53 as a target for the treatment of cancer. Cancer Treat. Rev. 40, 1153 1160 (2014).","DOI":"10.1016\/j.ctrv.2014.10.004"},{"key":"82542_CR14","unstructured":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327.e23 1341.e23 (2017)."},{"key":"82542_CR15","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.jhep.2014.08.009","volume":"61","author":"M Eichenm\u00fcller","year":"2014","unstructured":"Eichenm\u00fcller, M. et al. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J Hepatol 61, 1202\u20131204 (2014).","journal-title":"J Hepatol"},{"key":"82542_CR16","doi-asserted-by":"crossref","unstructured":"Chen, T. C., Hsieh, L. L. & Kuo, T. T. Absence of p53 gene mutation and infrequent overexpression of p53 protein in hepatoblastoma. J. Pathol. 176, 243 247 (1995).","DOI":"10.1002\/path.1711760306"},{"key":"82542_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.molmed.2009.09.005","volume":"15","author":"JD Amaral","year":"2009","unstructured":"Amaral, J. D., Castro, R. E., Steer, C. J. & Rodrigues, C. M. P. p53 and the regulation of hepatocyte apoptosis: implications for disease pathogenesis. Trends Mol. Med. 15, 531\u2013541 (2009).","journal-title":"Trends Mol. Med."},{"key":"82542_CR18","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.febslet.2012.02.049","volume":"586","author":"X Wang","year":"2012","unstructured":"Wang, X. & Jiang, X. Mdm2 and MdmX partner to regulate p53. FEBS Lett. 586, 1390\u20131396 (2012).","journal-title":"FEBS Lett."},{"key":"82542_CR19","doi-asserted-by":"crossref","unstructured":"Arai, Y. et al. Genome\u2010wide analysis of allelic imbalances reveals 4q deletions as a poor prognostic factor and MDM4 amplification at 1q32.1 in hepatoblastoma. Genes Chromosom. Cancer 49, 596\u2013609 (2010).","DOI":"10.1002\/gcc.20770"},{"key":"82542_CR20","doi-asserted-by":"crossref","unstructured":"Sumazin, P. et al. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology 65, 104 121 (2017).","DOI":"10.1002\/hep.28888"},{"key":"82542_CR21","doi-asserted-by":"crossref","unstructured":"Kim, T.-M. et al. Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int. J. Cancer 123, 2808 2815 (2008).","DOI":"10.1002\/ijc.23901"},{"key":"82542_CR22","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/hep.26954","volume":"59","author":"R Pellegrino","year":"2014","unstructured":"Pellegrino, R. et al. EEF1A2 inactivates p53 by way of PI3K\/AKT\/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. Hepatology 59, 1886\u20131899 (2014).","journal-title":"Hepatology"},{"key":"82542_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1158\/1535-7163.MCT-10-0581","volume":"10","author":"H Wang","year":"2011","unstructured":"Wang, H., Ma, X., Ren, S., Buolamwini, J. K. & Yan, C. A Small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol. Cancer Ther. 10, 69\u201379 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"82542_CR24","doi-asserted-by":"crossref","unstructured":"Cairo, S. et al. Hepatic stem-like phenotype and interplay of Wnt\/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 14, 471 484 (2008).","DOI":"10.1016\/j.ccr.2008.11.002"},{"key":"82542_CR25","unstructured":"Doi, I. Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gan 67, 1 10 (1976)."},{"key":"82542_CR26","doi-asserted-by":"crossref","unstructured":"Tanaka, M. et al. Production of fibronectin by HUH6 C15 cell line established from a human hepatoblastoma. Biochem. Biophys. Res. Commun. 110, 837 841 (1983).","DOI":"10.1016\/0006-291X(83)91037-9"},{"key":"82542_CR27","unstructured":"Pietsch, T. et al. Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab. Investig. J. Tech. Methods Pathol. 74, 809 818 (1996)."},{"key":"82542_CR28","doi-asserted-by":"crossref","unstructured":"Bissig-Choisat, B. et al. Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer. J. Hepatol. 65, 325 333 (2016).","DOI":"10.1016\/j.jhep.2016.04.009"},{"key":"82542_CR29","doi-asserted-by":"crossref","unstructured":"Gripon, P. et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. USA 99, 15655 15660 (2002).","DOI":"10.1073\/pnas.232137699"},{"key":"82542_CR30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/mutage\/ger076","volume":"27","author":"R Joss\u00e9","year":"2012","unstructured":"Joss\u00e9, R., Rogue, A., Lorge, E. & Guillouzo, A. An adaptation of the human HepaRG cells to the in vitro micronucleus assay. Mutagenesis 27, 295\u2013304 (2012).","journal-title":"Mutagenesis"},{"key":"82542_CR31","first-page":"1839","volume":"61","author":"YF Ramos","year":"2001","unstructured":"Ramos, Y. F. et al. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res. 61, 1839\u20131842 (2001).","journal-title":"Cancer Res."},{"key":"82542_CR32","doi-asserted-by":"crossref","unstructured":"Chang, Y. S. et al. Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl. Acad. Sci. 110, E3445 54 (2013).","DOI":"10.1073\/pnas.1303002110"},{"key":"82542_CR33","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844\u2013848 (2004).","journal-title":"Science"},{"key":"82542_CR34","doi-asserted-by":"publisher","first-page":"11465","DOI":"10.1038\/srep11465","volume":"5","author":"KI Pishas","year":"2015","unstructured":"Pishas, K. I. et al. XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. Sci. Rep-uk 5, 11465 (2015).","journal-title":"Sci. Rep-uk"},{"key":"82542_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fonc.2016.00007","volume":"6","author":"A Burgess","year":"2016","unstructured":"Burgess, A. et al. Clinical overview of MDM2\/X-targeted therapies. Front. Oncol. 6, 7 (2016).","journal-title":"Front. Oncol."},{"key":"82542_CR36","doi-asserted-by":"crossref","unstructured":"Wade, M., Li, Y.-C. & Wahl, G. M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 13, 83 96 (2013).","DOI":"10.1038\/nrc3430"},{"key":"82542_CR37","doi-asserted-by":"crossref","unstructured":"Aziz, M. H., Shen, H. & Maki, C. G. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene 30, 4678 4686 (2011).","DOI":"10.1038\/onc.2011.185"},{"key":"82542_CR38","doi-asserted-by":"crossref","unstructured":"Meric-Bernstam, F. et al. Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. J. Clin. Oncol. 35, 2505 2505 (2017).","DOI":"10.1200\/JCO.2017.35.15_suppl.2505"},{"key":"82542_CR39","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/jmcb\/mjz007","volume":"11","author":"S Haupt","year":"2019","unstructured":"Haupt, S., Mej\u00eda-Hern\u00e1ndez, J. O., Vijayakumaran, R., Keam, S. P. & Haupt, Y. The long and the short of it: the MDM4 tail so far. J. Mol. Cell Biol. 11, 231\u2013244 (2019).","journal-title":"J. Mol. Cell Biol."},{"key":"82542_CR40","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/msb.2010.107","volume":"6","author":"L Kapitzky","year":"2010","unstructured":"Kapitzky, L. et al. Cross-species chemogenomic profiling reveals evolutionarily conserved drug mode of action. Mol. Syst. Biol. 6, 451 (2010).","journal-title":"Mol. Syst. Biol."},{"key":"82542_CR41","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1158\/0008-5472.CAN-18-3066","volume":"79","author":"TP Howard","year":"2019","unstructured":"Howard, T. P. et al. MDM2 and MDM4 are therapeutic vulnerabilities in malignant rhabdoid tumors. Cancer Res. 79, 2404\u20132414 (2019).","journal-title":"Cancer Res."},{"key":"82542_CR42","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1084\/jem.20171066","volume":"215","author":"B Stolte","year":"2018","unstructured":"Stolte, B. et al. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. J. Exp. Med. 215, 2137\u20132155 (2018).","journal-title":"J. Exp. Med."},{"key":"82542_CR43","doi-asserted-by":"crossref","unstructured":"Gembarska, A. et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat. Med. 18, 1239 1247 (2012).","DOI":"10.1038\/nm.2863"},{"key":"82542_CR44","doi-asserted-by":"crossref","unstructured":"Jin, G. et al. HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. Neuro-oncology 12, 956 966 (2010).","DOI":"10.1093\/neuonc\/noq045"},{"key":"82542_CR45","doi-asserted-by":"crossref","unstructured":"Vu, B. et al. Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development. ACS Med. Chem. Lett. 4, 466 469 (2013).","DOI":"10.1021\/ml4000657"},{"key":"82542_CR46","doi-asserted-by":"crossref","unstructured":"Ding, Q. et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J. Med. Chem. 56, 5979 5983 (2013).","DOI":"10.1021\/jm400487c"},{"key":"82542_CR47","doi-asserted-by":"publisher","first-page":"278","DOI":"10.18632\/genesandcancer.120","volume":"7","author":"J Hern\u00e1ndez-Monge","year":"2016","unstructured":"Hern\u00e1ndez-Monge, J., Rousset-Roman, A. B., Medina-Medina, I. & Olivares-Illana, V. Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB. Genes Cancer 7, 278\u2013287 (2016).","journal-title":"Genes Cancer"},{"key":"82542_CR48","doi-asserted-by":"publisher","first-page":"19251","DOI":"10.1074\/jbc.C200150200","volume":"277","author":"J Gu","year":"2002","unstructured":"Gu, J. et al. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J. Biol. Chem. 277, 19251\u201319254 (2002).","journal-title":"J. Biol. Chem."},{"key":"82542_CR49","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1083\/jcb.200306009","volume":"162","author":"R Neef","year":"2003","unstructured":"Neef, R. et al. Phosphorylation of mitotic kinesin-like protein 2 by polo-like kinase 1 is required for cytokinesis. J. Cell Biol. 162, 863\u2013876 (2003).","journal-title":"J. Cell Biol."},{"key":"82542_CR50","doi-asserted-by":"crossref","unstructured":"Stangel, D. et al. Kif20a inhibition reduces migration and invasion of pancreatic cancer cells. J. Surg. Res. 197, 91 100 (2015).","DOI":"10.1016\/j.jss.2015.03.070"},{"key":"82542_CR51","doi-asserted-by":"crossref","unstructured":"Yan, G.-R. et al. Genistein-induced mitotic arrest of gastric cancer cells by downregulating KIF20A, a proteomics study. Proteomics 12, 2391 2399 (2012).","DOI":"10.1002\/pmic.201100652"},{"key":"82542_CR52","doi-asserted-by":"crossref","unstructured":"Saito, K., Ohta, S., Kawakami, Y., Yoshida, K. & Toda, M. Functional analysis of KIF20A, a potential immunotherapeutic target for glioma. J. Neuro-oncol. 132, 63 74 (2017).","DOI":"10.1007\/s11060-016-2360-1"},{"key":"82542_CR53","doi-asserted-by":"publisher","first-page":"e0167449","DOI":"10.1371\/journal.pone.0167449","volume":"11","author":"W Zhang","year":"2016","unstructured":"Zhang, W. et al. High expression of KIF20A is associated with poor overall survival and tumor progression in early-stage cervical squamous cell carcinoma. PLoS ONE 11, e0167449 (2016).","journal-title":"PLoS ONE"},{"key":"82542_CR54","doi-asserted-by":"crossref","unstructured":"Duan, J., Huang, W. & Shi, H. Positive expression of KIF20A indicates poor prognosis of glioma patients. OncoTargets Ther. 9, 6741 6749 (2016).","DOI":"10.2147\/OTT.S115974"},{"key":"82542_CR55","doi-asserted-by":"crossref","unstructured":"Imai, K. et al. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Br. J. Cancer 104, 300 307 (2011).","DOI":"10.1038\/sj.bjc.6606052"},{"key":"82542_CR56","doi-asserted-by":"crossref","unstructured":"Shi, C. et al. Aberrantly activated Gli2-KIF20A axis is crucial for growth of hepatocellular carcinoma and predicts poor prognosis. Oncotarget 7, 26206 26219 (2016).","DOI":"10.18632\/oncotarget.8441"},{"key":"82542_CR57","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1002\/cam4.1710","volume":"7","author":"X Zhao","year":"2018","unstructured":"Zhao, X. et al. Overexpression of KIF20A confers malignant phenotype of lung adenocarcinoma by promoting cell proliferation and inhibiting apoptosis. Cancer Med-us 7, 4678\u20134689 (2018).","journal-title":"Cancer Med-us"},{"key":"82542_CR58","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ajpath.2011.09.040","volume":"180","author":"I Gasnereau","year":"2012","unstructured":"Gasnereau, I. et al. KIF20A mRNA and its product MKlp2 are increased during hepatocyte proliferation and hepatocarcinogenesis. Am. J. Pathol. 180, 131\u2013140 (2012).","journal-title":"Am. J. Pathol."},{"key":"82542_CR59","doi-asserted-by":"crossref","unstructured":"Zhang, L., Scorsone, K., Woodfield, S. E. & Zage, P. E. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. Cancer Chemoth. Pharm. 76, 977 987 (2015).","DOI":"10.1007\/s00280-015-2871-z"},{"key":"82542_CR60","doi-asserted-by":"crossref","unstructured":"Budanov, A. V., Sablina, A. A., Feinstein, E., Koonin, E. V. & Chumakov, P. M. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science (New York, N.Y.) 304, 596 600 (2004).","DOI":"10.1126\/science.1095569"}],"updated-by":[{"DOI":"10.1038\/s41598-021-98174-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82542-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82542-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82542-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T21:59:55Z","timestamp":1670018395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82542-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["82542"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-82542-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,3]]},"assertion":[{"value":"23 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-021-98174-7","URL":"https:\/\/doi.org\/10.1038\/s41598-021-98174-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2967"}}